Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis HealthcareNSE:METROPOLIS -5.73%93 Pretax Margin % is 16.43% as of Mar. 2026, which is 25% below its 10-year median of 21.80. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 93/100 and a GF Value™ of ₹589.42 (Fairly Valued). The stock has 4 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 83.17% on this metric.
The historical rank and industry rank for Metropolis Healthcare's Pretax Margin % or its related term are showing as below:
NSE:METROPOLIS'
s Pretax Margin % Range Over the Past 10 Years
Min: 14.34 Med: 21.8 Max: 29.36
Current: 15.75
NSE:METROPOLIS's Pretax Margin % is ranked better than 83.17% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs NSE:METROPOLIS: 15.75
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Metropolis Healthcare Pretax Margin % Related Terms
Metropolis Healthcare Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metropolis Healthcare (NSE:METROPOLIS) has a Pretax Margin % of 16.43% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Metropolis Healthcare and its competitors. This is 25% below median its historical median of 21.80. Over the past decade, Metropolis Healthcare's Pretax Margin % has ranged from 14.34 to 29.36. According to the industry distribution chart, Metropolis Healthcare ranks #34 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 16.8%.
Is Metropolis Healthcare's Pretax Margin % too high?
Metropolis Healthcare's current Pretax Margin % of 16.43% is 25% below median its 10-year median of 21.80. Over the past 10 years, this metric has ranged from a low of 14.34 to a high of 29.36. Based on the distribution chart, Metropolis Healthcare ranks #34 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #34 out of 202 companies for Pretax Margin %. This places Metropolis Healthcare in the top 17% of its industry — outperforming the majority of peers. Historically, Metropolis Healthcare's own Pretax Margin % has ranged from 14.34 to 29.36 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Metropolis Healthcare and its competitors. Metropolis Healthcare's current Pretax Margin % is 16.43%, which is 25% below median its own 10-year median of 21.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹589.42, compared to a current price of ₹545.30 — trading 7.5% below its estimated fair value. The current Pretax Margin % is 16.43%, which is 25% below median its 10-year median of 21.80. Metropolis Healthcare's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current Pretax Margin % is 16.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹545.30 is trading 7.5% below its estimated GF Value™ of ₹589.42.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
Pretax Margin %: 16.43% (25% below median its 10-year median of 21.80)
GF Value™: ₹589.42 vs. price of ₹545.30 (7.5% below fair value)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
93GF Score
Get the complete analysis for NSE:METROPOLIS
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
